Exhibit 10.1

EXECUTION VERSION

WAIVER TO CREDIT AGREEMENT

This WAIVER AGREEMENT (this “Agreement”), dated as of February 9, 2011, is
entered into by and among K-V PHARMACEUTICAL COMPANY, a Delaware corporation
(the “Borrower”), certain of the Borrower’s subsidiaries, as guarantors
(collectively, the “Guarantors”), U.S. HEALTHCARE I, L.L.C., as Administrative
Agent and Collateral Agent (the “Agent”) and the LENDERS listed on the signature
pages hereto, and U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. and
is made with reference to that certain CREDIT AND GUARANTY AGREEMENT, dated as
of November 17, 2010 (as amended by that certain (i) Amended and Restated
Amendment No. 1 to Credit Agreement dated as of January 6, 2011, (ii) Waiver
Agreement dated as of January 14, 2011, (iii) Waiver Agreement dated as of
January 21, 2011, (iv) Waiver Agreement dated as of January 28, 2011, and
(v) Waiver Agreement dated as of February 4, 2011, the “Credit Agreement”) by
and among the Borrower, the Guarantors, the Lenders from time to time party
thereto and the Agent. Unless otherwise stated, capitalized terms used herein
without definition shall have the same meanings herein as set forth in the
Credit Agreement.

WHEREAS, the Credit Parties have failed to comply with the requirement set forth
in Section 6.7(b) of the Credit Agreement with respect to the calendar month of
December 2010 and, solely as a result of such non-compliance, an Event of
Default under Section 8.1(b) has occurred and is continuing (the “December
Covenant Default”);

WHEREAS, the Credit Parties anticipate that they may have failed to comply with
the requirement set forth in Section 6.7(b) of the Credit Agreement with respect
to the calendar month of January 2011 and, solely as a result of such
anticipated non-compliance, a Default has occurred and an Event of Default under
Section 8.1(b) may occur (such Default and potential Event of Default,
collectively, the “January Covenant Default”);

WHEREAS, the Credit Parties have failed to comply with the requirements set
forth in Section 5.14 of the Credit Agreement insofar as they have failed to
cause there to be effective a Control Agreement with respect to account no.
5590011846 at Bank of America, N.A. and, solely as a result of such
non-compliance, an Event of Default under 8.1(b) has occurred and is continuing
(the “Control Agreement Default”);

WHEREAS, the Credit Parties have failed to comply with the requirements set
forth in Section 5.16(b) of the Credit Agreement and, solely as a result of such
non-compliance, an Event of Default under Section 8.1(b) has occurred and is
continuing (the “Amendment Default”);

WHEREAS, the Credit Parties anticipate that they may fail to comply with the
requirement set forth in Section 6.7(a) of the Credit Agreement prior to the
Waiver Termination Date and, solely as a result of such anticipated
non-compliance, a Default has occurred and an Event of Default under
Section 8.1(b) may occur (such Default and potential Event of Default, together
with the December Covenant Default, the January Covenant Default, the Control
Agreement Default and the Amendment Default, collectively shall be referred to
herein as the “Waived Defaults”);

 

1

--------------------------------------------------------------------------------

WHEREAS, the Borrower has requested that the Agent and the Lenders temporarily
waive the Waived Defaults; and

WHEREAS, the Agent and the Lenders are willing to waive the Waived Defaults on
the terms and subject to the conditions specified herein.

NOW, THEREFORE in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereto agree as follows:

1. Confirmation of Obligations. The Borrower and the other Credit Parties
acknowledge and agree that the aggregate principal balance of the outstanding
Obligations under the Credit Agreement as of February 9, 2011 was not less than
$60,000,000. The foregoing amount does not include any of the interest, fees,
costs, and expenses to which Agent and Lenders are entitled under the Credit
Agreement or other Credit Documents. All of the foregoing Obligations are
outstanding, and the Borrower and the other Credit Parties agree and acknowledge
that (a) they are jointly and severally liable for the Obligations, and (b) they
have no right of offset, defense, or counterclaim with respect to any of the
Obligations or Liens securing same, and any such offset, defense, or
counterclaim is hereby waived.

2. Representations, Warranties and Acknowledgments by Credit Parties and by KV
Pharmaceutical. To induce the Agent and the Lenders to execute this Agreement,
each Credit Party hereby acknowledges, stipulates, represents, warrants and
agrees as follows (as of the date hereof):

(a) Other than the Waived Defaults, no Defaults or Events of Default have
occurred and are continuing through the date hereof.

(b) Prior to the date of this Agreement, nothing has occurred that constitutes a
waiver of any of the rights or remedies of the Lenders or the Agent.

(c) Each of the Borrower and the other Credit Parties has the full power,
authority and legal right to enter into this Agreement and all documents,
acknowledgments and instruments delivered in connection herewith, and this
Agreement and such other documents, acknowledgments and instruments have been
duly authorized by the board of directors or other governing body of the
applicable Credit Party.

(d) This Agreement, all documents, acknowledgments and instruments delivered in
connection herewith, the Credit Agreement, and the other Credit Documents
constitute the legal, valid and binding obligations of the Borrower and the
other Credit Parties and are enforceable against the Borrower and the other
Credit Parties in accordance with their respective terms.

(e) Neither the execution, delivery and performance of this Agreement and all
documents, acknowledgments and instruments delivered in connection herewith nor
the consummation of the transactions contemplated hereby or thereby does or
shall contravene, result in a breach of, or otherwise violate (i) any provision
of the Borrower’s or any other Credit Party’s corporate charter or bylaws or
other Organizational

 

2

--------------------------------------------------------------------------------

Documents or governing documents, and (ii) any law or regulation, any order or
decree of any court or government instrumentality, or any agreement or document
by which such party is bound, except in the case of clause (ii) to the extent as
such conflict, breach or violation could not reasonably be expected to result in
a Material Adverse Effect.

(f) Contemporaneously with the withdrawal referred to in Section 3(ii) of this
Agreement, the transfer of the Purchased Assets (as defined in the Gestene APA
(as amended though the date hereof)) shall occur and the Borrower shall, upon
such transfer, own the Purchased Assets.

(g) The Liens of the Agent and each Lender in and on the Collateral are and
continue to be valid, binding, perfected and enforceable Liens (with the
priorities required by the Credit Agreement and the other Credit Documents)
which secure the Obligations, and no tax or judgment liens are currently of
record against the Borrower or any other Credit Party (other than such tax or
judgment liens that constitute Permitted Liens).

3. Waiver. Solely during the Waiver Period (as defined below), the Lenders
hereby agree to (i) waive the Waived Defaults and to forbear from exercising any
of their respective rights and remedies under the Credit Documents against the
Borrower or the other Credit Parties that may exist by virtue of the Waived
Defaults and (ii) notwithstanding the conditions set forth in Section 3.2(a) of
the Credit Agreement, allow the Borrower to make a Tranche B-1 Withdrawal from
the B-1 Controlled Account in an amount not to exceed $13,763,000 so long as the
Borrower immediately applies the entire amount of such withdrawal towards,
first, the payment in full of the First Additional Purchase Price Payment on the
Transfer Date (each as defined in the Gestene APA (as amended though the date
hereof)) in accordance with Section 4.2(b)(i) of the Gestene APA (as amended
though the date hereof) and thereafter to expenses the Borrower has agreed to
pay to the seller under the Gestene APA. The Borrower acknowledges and agrees,
however, that it shall not request any additional withdrawals from the B-1
Controlled Account during the Waiver Period and that, from and after the Waiver
Termination Date (as defined below), the foregoing waiver and forbearance
agreement shall cease to be of any force or effect and the Credit Parties, the
Administrative Agent and the Lenders shall be restored to the position they
would have been in (and the Administrative Agent and the Lenders shall have all
rights and remedies otherwise available to them) in respect of the Waived
Defaults as if the foregoing waiver and forbearance had never been granted.

4. Certain Terms. For the purposes of this Agreement: (a) the term “Waiver
Period” means the period beginning on the Effective Date and ending on the
Waiver Termination Date; (b) the term “Waiver Termination Date” means the
earliest to occur of (i) 12:00 p.m. (New York City time) on February 18, 2011
and (ii) the date on which there occurs a Waiver Default; and (c) the term
“Waiver Default” means the occurrence of any Default or Event of Default other
than the Waived Defaults.

5. Agreement to Negotiate Amendments. During the Waiver Period, the parties
hereto agree to in good faith negotiate modifications and amendments to each of
(a) the Credit Agreement, (b) any other Credit Documents and (c) the Commitment
Letter, dated as of November 17, 2010, by and among the Borrower and the Lenders
(including Exhibit A attached thereto) substantially upon the terms and
conditions set forth in the term sheet attached hereto as Exhibit A.

 

3

--------------------------------------------------------------------------------

6. Issuance of Warrants. On or prior to the second Business Day to occur after
the tenth (10th) day after February 14, 2011, (a) Borrower shall deliver to the
Agent (i) an original counterpart signature page of the Stock Purchase Warrant
(the “Additional Warrants”) substantially in the form attached hereto as Exhibit
B, duly executed by the Borrower and (ii) copies of the favorable written
opinions of counsel to the Credit Parties, each in form and substance reasonably
satisfactory to the Agent (and each Credit Party hereby instructs such counsel
to deliver such opinions to the Agent) with respect to the Additional Warrants
and the transactions contemplated thereby (it being agreed that such opinions
shall be satisfactory to the Agent to the extent that such opinions are
substantially the same as the opinions delivered to the Agent in connection with
the Warrants issued on or about the Closing Date) and (b) the Additional
Warrants shall be in full force and effect and shall have been issued and
delivered to the Lenders.

7. Conditions Precedent. This Agreement shall be effective on the date (the
“Effective Date”) when each of the following conditions precedent shall have
been satisfied:

(a) The Agent shall have received (i) a counterpart signature page of this
Agreement duly executed by each of the Credit Parties and the Lenders, (ii) a
counterpart signature page of the Stock Warrant Purchase Agreement (the
“Additional Warrant Agreement”) substantially in the form attached hereto as
Exhibit C, duly executed by the Borrower and (iii) a counterpart signature page
of the Amended and Restated Registration Rights Agreement (the “A&R Registration
Rights Agreement” and, together with the Additional Warrant Agreement, the
“Additional Equity Documents”) substantially in the form attached hereto as
Exhibit D, duly executed by the Borrower.

(b) Each of the Additional Equity Documents shall be in full force and effect.

(c) The Agent shall have received all fees and other amounts due and payable to
the Agent on or prior to the date hereof and to the extent invoiced prior to the
date hereof.

(d) Each Credit Party shall have obtained all material consents necessary or
advisable in connection with the transactions contemplated by this Agreement.

(e) The Transfer Date (as defined in the Gestene APA (as amended though the date
hereof)) shall have occurred or shall occur simultaneously with the Effective
Date.

(f) The Agent and Lenders shall have received such other documents, information
or agreements regarding Credit Parties as Agent or Collateral Agent may
reasonably request.

 

4

--------------------------------------------------------------------------------

8. Release. The Credit Parties hereby waive, release, remise and forever
discharge the Agent, Lenders and each other Indemnitee from any and all actions,
causes of action, suits or other claims of any kind or character, known or
unknown, which any Credit Party ever had, now has or might hereafter have
against the Agent, any Lender or any other Indemnitee which relate, directly or
indirectly, to any acts or omissions of the Agent, any Lender or any other
Indemnitee on or prior to the date hereof arising out of, in connection with, or
otherwise relating to, the Credit Documents or any matter in connection
therewith.

9. Limited Effect of Agreement. Except as expressly provided in this Agreement,
the Credit Agreement and each other Credit Document, shall continue to be, and
shall remain, in full force and effect. This Agreement shall not be deemed or
otherwise construed to be a commitment or any other undertaking or expression of
any willingness to engage in any further discussion with any Credit Party or any
other Person with respect to any waiver, amendment, modification or any other
change to the Credit Agreement or any other Credit Document, or any rights or
remedies arising in favor of the Agent and the Lenders under or with respect to
any such documents.

10. Amendment to Agreement. No term of this Agreement (or the exhibits and
schedules attached hereto) may be waived, modified or amended except in a
writing signed by the Agent, the Lenders and the Credit Parties.

11. No Waiver. Except as expressly provided to the contrary in this Agreement,
all the terms, conditions and provisions of the Credit Agreement and other
Credit Documents shall continue in full force and effect.

12. Credit Documents. The parties hereto acknowledge and agree that this
Agreement, and when delivered, the Additional Warrants and the Additional Equity
Documents, and each other document executed and delivered in connection with the
forgoing constitute Credit Documents for the purposes of the Credit Agreement
and any other Credit Document. Furthermore, the failure of the Borrower to
comply with the terms and conditions set forth in this Agreement, the Additional
Warrants or the Additional Equity Documents shall constitute an immediate Event
of Default (without giving effect to any grace or cure periods with respect
thereto).

13. WAIVER OF JURY TRIAL. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.

14. Severability. Wherever possible, each provision of this Agreement shall be
interpreted in such a manner as to be effective and valid under applicable law,
but if any provision of this Agreement shall be prohibited by or invalid under
applicable law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Agreement.

15. GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER SHALL BE GOVERNED BY, AND SHALL

 

5

--------------------------------------------------------------------------------

BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK,
WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THEREOF.

16. Survival. All representations, warranties, covenants and agreements made
herein shall survive the execution, delivery and consummation of this Agreement.

17. Section Headings. Section headings in this Agreement are included herein for
convenience of reference only and shall not constitute a part of this Agreement
for any other purposes.

18. Counterparts; Electronic Execution. This Agreement may be executed in any
number of counterparts and by different parties on separate counterparts, each
of which when so executed shall be deemed to be an original and all of which
taken together shall constitute but one and the same agreement. Delivery of an
executed counterpart of this Agreement by electronic or facsimile transmission
shall be as effective as delivery of a manually executed counterpart of this
Agreement.

[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

 

6

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties hereto have caused this Waiver Agreement to be
executed by their respective officers thereunto duly authorized as of the date
first above written.

 

K-V Pharmaceutical Company, as the Borrower By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
Zeratech Technologies USA, Inc., as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
DrugTech Corporation, as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
ETHEX Corporation, as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
FP1096, Inc., as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
Nesher Pharmaceuticals Inc., as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer

 

[Signature Page to Waiver]

--------------------------------------------------------------------------------

Nesher Solutions USA, Inc., as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
Nesher Discovery Solutions, Inc., as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer
Ther-Rx Corporation, as a Guarantor By:  

/s/ Gregory J. Divis

  Name:   Gregory J. Divis   Title:   President and Chief Executive Officer

--------------------------------------------------------------------------------

U.S. HEALTHCARE I, L.L.C., as Agent and a Lender By:  

/s/ Kevin Fusco

  Name:   Kevin Fusco   Title:   Authorized Signatory

U.S. HEALTHCARE II, L.L.C.,

as a Lender

By:  

/s/ Kevin Fusco

  Name:   Kevin Fusco   Title:   Authorized Signatory

--------------------------------------------------------------------------------

EXHIBIT A

Amendment Term Sheet

--------------------------------------------------------------------------------

EXHIBIT B

Stock Purchase Warrant

--------------------------------------------------------------------------------

EXHIBIT C

Stock Warrant Purchase Agreement

--------------------------------------------------------------------------------

EXHIBIT D

Amended and Restated Registration Rights Agreement